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Abstract
Background. Both neurodegenerative and neurodevelopmental abnormalities have been sug-
gested to be part of the etiopathology of severe mental illness (SMI). Neuron-specific enolase
(NSE), mainly located in the neuronal cytoplasm, may indicate the process as it is upregulated
after neuronal injury while a switch from non-neuronal enolase to NSE occurs during neur-
onal maturation.
Methods. We included 1132 adult patients with SMI [schizophrenia (SZ) or bipolar spectrum
disorders], 903 adult healthy controls (HC), 32 adolescent patients with SMI and 67 adoles-
cent HC. Plasma NSE concentrations were measured by enzyme immunoassay. For 842 adults
and 85 adolescents, we used total grey matter volume (TGMV) based on T1-weighted mag-
netic resonance images processed in FreeSurfer v6.0. We explored NSE case-control differ-
ences in adults and adolescents separately. To investigate whether putative case-control
differences in NSE were TGMV-dependent we controlled for TGMV.
Results. We found significantly lower NSE concentrations in both adult ( p < 0.001) and ado-
lescent patients with SMI ( p = 0.007) compared to HC. The results remained significant after
controlling for TGMV. Among adults, both patients with SZ spectrum ( p < 0.001) and bipolar
spectrum disorders ( p = 0.005) had lower NSE than HC. In both patient subgroups, lower
NSE levels were associated with increased symptom severity. Among adults ( p < 0.001) and
adolescents ( p = 0.040), females had lower NSE concentrations than males.
Conclusion. We found lower NSE concentrations in adult and adolescent patients with SMI
compared to HC. The results suggest the lack of progressive neuronal injury, and may reflect
abnormal neuronal maturation. This provides further support of a neurodevelopmental rather
than a neurodegenerative mechanism in SMI.
Introduction
Schizophrenia (SZ) and bipolar disorder (BD) are severe mental illnesses (SMIs) each affecting
approximately 1% of the population (Kahn et al., 2015; Vieta et al., 2018). The disorders are
leading causes of disability, have a complex and largely unknown etiopathology (Kahn et al.,
2015; Kloiber et al., 2020), are highly heritable (Mullins et al., 2021; Smeland, Frei, Dale, &
Andreassen, 2020) and stigmatised (Hawke, Parikh, & Michalak, 2013; Serafini et al., 2011;
Valery & Prouteau, 2020). Several lines of evidence indicate neurodevelopmental abnormalities
in SMI (Kinros, Reichenberg, & Frangou, 2010; O’Shea & McInnis, 2016; Owen, O’Donovan,
Thapar, & Craddock, 2011). Furthermore, there are indications of enhanced neurodegenera-
tion with increasing symptom load over time, cognitive decline and progressive brain changes
(Goodwin, Martinez-Aran, Glahn, & Vieta, 2008; Lieberman, 1999; Vieta et al., 2018).
Enolases are enzymes that participate in glycolysis and gluconeogenesis. In particular, eno-
lases catalyse the conversion of 2-phosphoglycerate to phosphoenolpyruvate in glycolysis, and
the reverse reaction in gluconeogenesis (Isgro, Bottoni, & Scatena, 2015). In vertebrates, there
are three dimeric isoforms: the non-neuronal enolase (NNE) or enolase 1, the neuron-specific
enolase (NSE) or enolase 2, and the muscle-specific enolase or enolase 3 (Haque, Polcyn,
Matzelle, & Banik, 2018). In the central nervous system, both NSE and NNE are expressed
(Haque et al., 2018; Isgro et al., 2015). NSE, first described in 1965 (Moore & McGregor,
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1965), is a soluble protein present mainly in the cytoplasm of neu-
rons, both in the cortex and in subcortical regions, and constitutes
a significant fraction of the total soluble protein of the brain
(Marangos & Schmechel, 1987).
Increased cerebrospinal fluid (CSF) and circulating (plasma/
serum) NSE concentrations indicate neuronal damage (Haque
et al., 2018; Isgro et al., 2015). In particular, elevated NSE reflects
neuronal damage after traumatic brain injury (Cheng, Yuan,
Yang, Wang, & Liu, 2014) and may also indicate oxidative damage
underlying neurodegenerative disorders (Haque et al., 2018).
Circulating NSE levels were higher in symptomatic Huntington’
disease (Ciancarelli et al., 2015), and CSF (Schmidt et al.,
2014) but not circulating (Chaves et al., 2010) NSE levels were
elevated in Alzheimer’s disease, whereas the NSE literature in
Parkinsonian syndromes is conflicting (Constantinescu, Zetterberg,
Holmberg, & Rosengren, 2009; Schaf et al., 2005). Increased
CSF NSE has also been shown in neurological disorders with
rapid progression such as Guillain–Barré syndrome (Mokuno
et al., 1994) and Creutzfeldt–Jakob disease (Aksamit, Preissner,
& Homburger, 2001). If SMIs are neurodegenerative disorders
with ongoing neuronal damage, circulating NSE levels might be
increased.
NSE is also involved in neuronal differentiation, maturation
and migration (Haque et al., 2018; Isgro et al., 2015; Marangos &
Schmechel, 1987). In the mammalian embryonic brain and in pri-
mary neuron cultures, undifferentiated neurons have been shown
to contain mainly NNE, whereas a switch to NSE occurs during
the neuronal maturation process and cell migration (Marangos &
Schmechel, 1987; Marangos, Schmechel, Parma, & Goodwin,
1980b; Schengrund & Marangos, 1980; Schmechel, Brightman, &
Marangos, 1980). It has been suggested that the key to the develop-
ment of psychosis is early (pre- and perinatal) but also late (during
adolescence) neurodevelopmental disturbances (Brent, Thermenos,
Keshavan, & Seidman, 2013). There is indication of neuronal mat-
uration disturbances in both SZ and BD (Gandal, Nesbitt,
McCurdy, & Alter, 2012; Hagihara, Ohira, Takao, & Miyakawa,
2014; Hagihara, Takao, Walton, Matsumoto, & Miyakawa, 2013;
Torkamani, Dean, Schork, & Thomas, 2010; Walton et al., 2012).
In the prefrontal cortex (PFC) of patients with SZ, the normal
age-related decline in gene expression associated with developmen-
tal processes, including neuronal differentiation, is slowed
(Torkamani et al., 2010). Hagihara et al. have shown a transcrip-
tional immaturity in the PFC of patients with SZ that was not
due to medication effects (Hagihara et al., 2014). Further,
fast-spiking interneurons, the primary cells for synaptic inhibition,
have been suggested to be immature in the cortex of patients with
SZ and BD (Gandal et al., 2012). Finally, both animal models and
post-mortem studies have indicated an immature hippocampal
dentate gyrus endophenotype in SZ and BD, with abundant imma-
ture granule cells (Hagihara et al., 2013; Walton et al., 2012). Thus,
if circulating NSE reflects such disturbances, one might expect
lower NSE levels in SMI than in HC.
Previous studies with small sample sizes have shown unaltered
circulating NSE levels in SZ (Egan et al., 1992; Schroeter, Abdul-
Khaliq, Krebs, Diefenbacher, & Blasig, 2009; Steiner, Bielau,
Bernstein, Bogerts, & Wunderlich, 2006), while studies of circulat-
ing NSE in BD have shown conflicting results (Akcan, Karabulut,
Ismail Kucukali, Cakir, & Tuzun, 2018; Karabulut et al., 2019;
Machado-Vieira et al., 2007; Tsai & Huang, 2017; Wiener et al.,
2013). The study of circulating NSE levels in a large-scale context
might provide more conclusive answers. Herein, we hypothesise
that circulating NSE concentrations in adult and adolescent
patients with SMI are either increased (indicating progressive
neuronal damage) or decreased (suggesting neural maturation
disturbance).
We further aimed to explore whether putative case-control dif-
ferences in circulating NSE are dependent on total grey matter
volume (TGMV). Smaller total or regional grey matter volumes
have been reported in SMI (Haijma et al., 2013; Hibar et al.,
2016; Wang et al., 2019), even in first-episode psychosis and in
patients at high risk for psychosis (Fusar-Poli, Smieskova,
Serafini, Politi, & Borgwardt, 2014). As neurons are the main
cells producing NSE (Marangos & Schmechel, 1987), it has
been hypothesised, but never shown, that smaller grey matter vol-
ume is associated with reduced circulating NSE concentrations
(Hoffmann et al., 2017). In a population-based study, Hoffmann
et al. reported no significant association (Hoffmann et al., 2017),




Patients were recruited from outpatient and inpatient psychiatric
units in Norway, as part of the Thematically Organised Psychosis
(TOP) research study (adult participants) and the TOP-Study for
Youth (Youth-TOP; adolescent participants). Healthy controls
(HC) were recruited from the same catchment area as the patients
using the national population register. The TOP research study
and the Youth-TOP research study are the main study protocols
at the Norwegian Centre for Mental Disorders Research
(NORMENT, Oslo, Norway; www.med.uio.no/norment/english),
for adults and adolescents, respectively. For the current study,
participants were drawn from the TOP and the Youth-TOP
study cohorts if NSE data were available. Patients were included
if they were diagnosed with SZ spectrum or BD spectrum disor-
ders according to DSM-IV as described below. The following
exclusion criteria were applied for all participants: previous mod-
erate or severe head injury, neurological disorders or medical con-
ditions that could affect brain function. In addition, to the best of
our knowledge, none of the participants had medical conditions
associated with increased circulating NSE levels including haemo-
lytic anaemia (Geisen et al., 2015), hepatic failure (Strauss et al.,
2001), end-stage renal disease (Davis et al., 2011) or a history of
NSE-secreting tumours, i.e. neuroendocrine tumours, lung can-
cer, mainly small-cell lung cancer, neuroblastoma, melanoma,
seminoma or other rare tumours where raised NSE levels have
been observed (renal cell carcinoma, carcinoid tumours, dysger-
minomas and immature teratomas) (Isgro et al., 2015). HC with
previous or current psychiatric disorders including substance
use disorder (including alcohol use disorder) or with first-degree
relatives with SMI were excluded. Adolescent patients who met
the criteria for substance use disorder (including alcohol use dis-
order) were also excluded.
Adult sample (TOP study)
We included 1132 adult patients with SMI and 903 adult HC (age
range 18–65 years). We enrolled patients with SZ spectrum disor-
ders (n = 735), i.e. patients with SZ (n = 424), schizophreniform
disorder (n = 44), schizoaffective disorder (n = 103), delusional
disorder (n = 45), brief psychotic disorder (n = 11), psychotic dis-
order not otherwise specified (NOS) (n = 108), and patients with
BD spectrum (n = 397), i.e. BD I (n = 249), BD II (n = 128) and
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BD NOS (n = 20). Medical doctors and psychologists assessed the
patients with the Structured Clinical Interview for DSM-IV axis I
disorder (SCID-I) module A–E (Spitzer, Williams, Gibbon, &
First, 1988). HC were assessed for exclusion criteria including
the use of Primary Care Evaluation of Mental Disorders
(Prime-MD) (Spitzer et al., 1994).
Adolescent sample (Youth-TOP study)
We included 32 adolescent patients with SMI (early-onset psych-
osis; onset of illness <18 years of age) (Werry, McClellan, &
Chard, 1991) and 67 adolescent HC (age range 12–18 years).
We enrolled patients with SZ (n = 17), schizoaffective disorder
(n = 1), brief psychotic disorder (n = 1), psychotic disorder NOS
(n = 11) and BD I with psychotic features (n = 2), according to
the DSM-IV. Medical doctors and psychologists assessed the
patients and HC with the Schedule for Affective Disorders and
Schizophrenia for School Aged Children-Present and Lifetime
Version (K-SADS-PL) (Kaufman et al., 1997).
Measures and medication
We evaluated the patients with the Positive and Negative
Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987) and
the Young Mania Rating Scale (YMRS) (Young, Biggs, Ziegler,
& Meyer, 1978). PANSS is a 30-item standardised clinical inter-
view for the assessment of positive (seven items) and negative
symptoms (seven items) as well as general psychopathology
(16 items) related to psychosis. The PANSS total score ranges
from 30 to 210 (positive scale: 7–49, negative scale: 7–49, general
psychopathology scale 16–112) with higher scores indicating
increased symptom severity (Kay et al., 1987). YMRS is an
11-item interviewer rating scale used to evaluate manic symptoms.
The ‘irritability’, ‘speech’, ‘thought content’ and ‘disruptive-
aggressive behaviour’ items are double weighted, and the YMRS
total score ranges from 0 to 60 with higher scores indicating
more severe manic symptoms (Young et al., 1978).
We assessed the current use (yes/no) of antipsychotic, antiepi-
leptic, lithium, and antidepressive medication, and for patients on
antipsychotics we calculated the current chlorpromazine equiva-
lent doses (CPZ) in mg/day (Andreasen, Pressler, Nopoulos,
Miller, & Ho, 2010). In the adolescent sample we had information
on lifetime antipsychotic medication exposure, and calculated life-
time CPZ (CPZ years) (Andreasen et al., 2010). We defined the
age of onset as the age at first psychotic episode in SZ spectrum
and at first-affective episode in BD spectrum. In adults, we eval-
uated alcohol use with the alcohol use disorder identification test
(AUDIT) (Bohn, Babor, & Kranzler, 1995) and drug use with the
drug use disorder identification test (DUDIT) (Berman, Bergman,
Palmstierna, & Schlyter, 2005).
NSE measurement
Plasma levels of NSE were measured in duplicate by enzyme
immunoassays (EIA) using commercially available antibodies
(R&D Systems, Minneapolis, MN, USA) in a 384 format using
a combination of a SELMA (Jena, Germany) pipetting robot
and a BioTek (Winooski, VT, USA) dispenser/washer.
Absorption was read at 450 nm with wavelength correction set
to 540 nm using an ELISA plate reader (Bio-Rad, Hercules, CA,
USA). Blood was sampled on ethylenediaminetetraacetic acid
vials, and the plasma was isolated and stored at −80°C. Blood
sampling was performed between 8 am and 5 pm with some vari-
ation between patients and HC. We found no effect of diurnal
variation comparing non-fasting levels in individuals at 8 am
and 4 pm [n = 6, within-patient coefficient of variation (CV) =
16%, p = 0.43] or postprandial variation comparing fasting and
non-fasting samples at 8 am (n = 6, within-patient CV = 12%, p
= 0.38). Validation of the NSE assay revealed intra- and inter-
assay variation of 4.9% and 10.3%, respectively. NSE was stable
at room temperature for 4 h (n = 4, within subject CV = 8.0%)
and for 24 h at 4 °C (n = 4, within subject CV = 11.2%).
Sensitivity, defined as the readout of 3×S.D. (standard deviation)
of low samples, was 62 pg/ml.
Total grey matter volume
Among adults, we obtained 842 T1-weighted magnetic resonance
imaging (MRI) scans with two 3T General Electric platforms:
411 scans were obtained using a GE 3T Signa HDxt scanner
with an eight-channel head, and 431 scans using a GE 3T
Discovery 750 scanner with a 32-channel head coil. Among ado-
lescents, 85 T1-weighted MRI scans were obtained using the same
scanners: 49 scans were acquired using the GE Signa HDxt system
and 36 scans were acquired using the GE Discovery 750 system.
The acquisition sequences used are described in online
Supplementary material.
In order to obtain the TGMV, all MRI scans were processed
using FreeSurfer v6.0 (Fischl, 2012). TGMV was calculated as
the sum of the cerebral cortical volume, the subcortical grey
matter and the cerebellum grey matter (https://surfer.nmr.mgh.
harvard.edu/fswiki/MorphometryStats). Quality inspection and
editing was performed by trained research assistants following
standard FreeSurfer procedures (McCarthy et al., 2015).
Statistics
All analyses were conducted separately for the adult and the ado-
lescent samples. The distribution of the NSE concentrations was
highly positively skewed in both samples, and we applied logarith-
mic transformations (log10) to normalise the data. The logNSE
concentrations were approximately normally distributed in both
samples (online Supplementary Figs S1 and S2). In the bivariate
analysis, we assessed group differences between patients and HC
in sex, age and body mass index (BMI) as well as the correlations
among each of these variables and logNSE. In the patient group,
we also investigated putative correlations between age of onset,
duration of illness (DOI), PANSS total score, YMRS score and
medication variables, and logNSE (Table 1). In our multivariate
models, we investigated putative associations between disease
status (patients v. HC) and logNSE concentrations, controlling
for variables that were significantly correlated with logNSE in
the bivariate analysis. For the main analyses, we computed par-
tial eta-squared, one of the most largely used effect size belong-
ing to the r family (Lakens, 2013). Partial eta-squared measures
the strength of the patient/control-logNSE association and
describes the proportion of variance in logNSE explained by
the patient/control status. In adults, we also explored putative
NSE level differences between patient subgroups (SZ spectrum
and BD spectrum) and HC. In the TGMV analysis, we in








Patients and HC differed significantly in age and BMI with lower
mean age and higher mean BMI in the patients (Table 1). Sex,
but not age (see online Supplementary Fig. S3 for visualisation of
the lack of age-logNSE correlation) or BMI, was correlated with
logNSE assessed with point-biserial correlation, rpb =−0.117,
p < 0.001, with lower logNSE in females than males, and sex
was therefore included in the multivariate analysis. Among pat-
ients, the PANSS total score was inversely correlated with
logNSE assessed with Spearman’s correlation, rs =−0.059, p =
0.049. In the multivariate model (analysis of variance, ANOVA),
there was a highly significant main effect of disease status (SMI/
HC) on logNSE, F = 27.296, p < 0.001, partial eta-squared (η2) =
0.013, with lower logNSE in patients than in HC (Fig. 1a).
Sex had also a significant effect on logNSE, F = 27.305, p < 0.001,
η2 = 0.013, with lower logNSE in women than men. The sex effect
was also present when we stratified the analysis by disease status,
such that both women with SMI had lower logNSE than men
with SMI ( p < 0.001) and healthy women had lower logNSE
than healthy men ( p = 0.011).
We separated the adult patients into SZ spectrum (n = 735)
and BD spectrum (n = 397). The bivariate analysis showed that
there were significant sex, age and BMI differences between SZ
spectrum, BD spectrum and HC (online Supplementary
Table S1). Only sex was correlated with logNSE (Table 1) and
was accounted for in the multivariate analysis. In the multivariate
model (ANOVA), there was a highly significant main effect of
disease status on logNSE, F = 14.762, p < 0.001. We ran three
pairwise comparisons and accepted statistical significance at a
Bonferroni-adjusted alpha level of 0.017 (0.05/3). Pairwise com-
parisons showed that both patients with SZ spectrum and
BD spectrum disorders had significantly lower logNSE than HC
( p < 0.001 and p = 0.005, respectively), whereas there was no
significant difference in logNSE between the two patient groups
( p = 0.137) (Fig. 1b). There was still a significant main effect of
sex on logNSE, F = 28.951, p < 0.001. Finally, we followed up the
logNSE-PANSS correlation described in the previous paragraph.
Stratifying by diagnostic group (SZ spectrum/BD spectrum) and
controlling for sex, we ran two multiple linear regressions and
showed that logNSE was significantly inversely associated
with PANSS total score in SZ spectrum (n = 719, β =−0.105,
p = 0.005), but not in BD spectrum (n = 395, β =−0.098, p =
0.059). Multiple linear regressions on PANSS positive, negative
and general scores, adjusting for sex, showed that in SZ spectrum,
logNSE was inversely associated with the positive (b = −0.092, p =
0.014), the general (b = −0.088, p = 0.019) but not the negative
PANSS score, while in BD spectrum, with the positive score
(β =−0.111, p = 0.029) only.
For both multivariate analyses, we also applied full factorial
models where we included both factors and their interaction;
there were no significant disease status-by-sex interactions ( p =
0.185 and 0.112 for the interaction in SMI/HC and SZ spec-
trum/BD spectrum/HC analysis, respectively). As both age and
BMI differed among the analysed groups (Table 1 and online
Supplementary Table S1), we inserted both variables as covariates
in both multivariate models. In the SMI/HC ANCOVA (analysis
of covariance), the associations between disease status ( p = 0.002)
and sex ( p < 0.001) with logNSE remained significant, whereas
age ( p = 0.665) and BMI ( p = 0.547) were not significantly
associated with logNSE in line with the results of the bivariate ana-
lysis. In the SZ spectrum/BD spectrum/HC ANCOVA, the corre-
sponding p-values were 0.002, <0.001, 0.803, and 0.513.
Adolescent sample
Patients and HC did not significantly differ in sex, age or BMI
(Table 1). As in adults, sex, but not age or BMI, was correlated
with logNSE, rpb =−0.225, p = 0.025, with lower logNSE in
females than males, and sex was thereby included in the multi-
variate analysis. Among patients, DOI was inversely correlated
with logNSE, rs =−0.419, p = 0.021. In the multivariate model
(ANOVA), there was a significant main effect of disease status
on logNSE, F = 7.672, p = 0.007, η2 = 0.074, with lower logNSE
in patients than in HC (Fig. 2). Also sex had a significant effect
on logNSE, F = 4.318, p = 0.04, η2 = 0.043, with lower logNSE in
females than in males. We finally applied a full factorial model
showing no disease status-by-sex interaction ( p = 0.416 for the
interaction).
Total grey matter volume analysis
We included 333 adult patients and 509 adult HC (adult MRI
sample), and 24 adolescent patients and 61 adolescent HC (ado-
lescent MRI sample). In both samples, females had smaller
TGMV than males ( p < 0.001 for both) assessed with t tests,
while age was negatively correlated with TGMV assessed with
Spearman’s correlations ( p < 0.001 and p = 0.005, respectively).
Applying ANCOVAs controlling for sex, age and scanner, patients
had lower TGMV than HC in the adult but not the adolescent
sample (Table 1). TGMV was not correlated with logNSE in
any sample (Table 1).
In order to evaluate a putative TGMV influence on our main
results, we first repeated the main ANOVAs in our MRI samples,
and subsequently added the TGMV and scanner variables and ran
ANCOVAs. In adults, the disease status effect ( p = 0.011 and
0.013 in the ANOVA and the ANCOVA, respectively) and the
sex effect ( p < 0.001 in both analyses) on logNSE were significant.
In the adolescent sample, the corresponding p-values were 0.001,
<0.001, 0.337 and 0.069.
Medication and substance use analysis
Among adults, we restricted the analysis to patients not currently
on any psychotropic medication (n = 156) and HC, and applied
an ANOVA to determine main effects of disease status and sex
on logNSE. Both disease status and sex had still significant
main effects on logNSE, with lower logNSE in patients than HC
( p = 0.004) and in women than men ( p = 0.001). Among adult
patients, the current use of lithium ( p = 0.003) and the CPZ
( p = 0.023) were positively correlated with logNSE. Among ado-
lescent patients, neither current use of antipsychotics, CPZ nor
CPZ years were significantly correlated with logNSE (Table 1).
Among adults, restricting the analysis to participants with a
zero DUDIT score and controlling for the AUDIT score did
not change the results ( p < 0.001 for both disease status and sex
effect on logNSE) (online Supplementary Material).
Discussion
We showed that circulating NSE levels were significantly lower in
adult and adolescent patients with SMI compared to HC, and in
adults, the same pattern was seen in SZ and BD spectra. The
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results remained significant after controlling for TGMV, dimin-
ishing the possibility that the lower NSE levels in the patient
groups reflect smaller TGMV.
CSF NSE concentrations in SZ have been investigated by
others, but the results have been contradictory most probably
due to the small sample size used (Egan et al., 1992; Li, Wu,
Guo, & Zhao, 2006; Steiner et al., 2006; Vermuyten, Lowenthal,
& Karcher, 1990). Circulating NSE has been explored in SZ in
studies of small sample sizes (25 to 39 participants) all showing
the lack of significant NSE difference between patients and HC
(Egan et al., 1992; Schroeter et al., 2009; Steiner et al., 2006).
Circulating NSE levels have also been explored in BD with con-
flicting results with a recent meta-analysis reporting the lack of
association with the illness (Bartoli, Misiak, Crocamo, & Carra,
2020). In line with our results, Wiener et al. reported lower
serum NSE levels in unmedicated patients with BD (n = 36,
mean age 28 years) compared to HC (n = 36, mean age 28
years) (Wiener et al., 2013). Machado-Vieira et al. showed lower
Table 1. Group differences between adult patients with SMI and HC as well as adolescent patients with SMI and HC
Patients with SMI Healthy controls Correlation with logNSE
Na Mean (S.D.) or % Na Mean (S.D.) or % p Valueb
Direction
(+ or −) p Valuec
Adult sample
Sex (% females) 1132 48.3 903 45.6 0.226 −d <0.001
Age (years) 1132 32.3 (10.7) 903 33.6 (9.2) 0.004 + 0.252
BMI (kg/m2) 1068 26.2 (5.3) 706 24.5 (3.7) <0.001 + 0.354
TGMV (mm3) 333 689 048 (64 796) 509 699 739 (60 900) 0.015e + 0.177
Age of onset (years) 1105 22.8 (8.4) + 0.116
DOI (years) 1105 9.6 (9.1) − 0.461
On antipsychotics (%) 1121 72 − 0.124
CPZ (mg/day) 781 313.5 (236.1) + 0.023
On lithium (%) 1121 8.4 + 0.003f
On antiepileptics (%) 1121 20.5 + 0.504
On antidepressants (%) 1121 29.9 − 0.091
PANSS total score 1114 56.2 (16.5) − 0.049
YMRS score 978 4.3 (4.9) − 0.353
Adolescent sample
Sex (% females) 32 62.5 67 52.24 0.337 −d 0.025
Age (years) 32 16.5 (1.3) 67 16 (1.4) 0.095 − 0.284
BMI (kg/m2) 27 23 (5.5) 54 21.1 (3.2) 0.225g + 0.761
TGMV (mm3) 24 708 856 (58 658) 61 751 087 (69 388) 0.010e − 0.489
Age of onset (years) 30 14.5 (2) + 0.086
DOI (years) 30 1.1 (2.7)h − 0.021
On antipsychotics (%) 32 59.4 + 0.793
CPZ (mg/day) 19 260.7 (163.2) + 0.656
CPZ years 21 5.4 (27)h − 0.268
PANSS total score 27 72.1 (16) − 0.652
YMRS score 28 2.9 (3.8) − 0.268
Group differences between adult patients with severe mental illness (SMI) and healthy controls (HC) as well as adolescent patients with SMI and HC in sex, age, body mass index (BMI) and
total grey matter volume (TGMV). In patients, age of onset, duration of illness (DOI), Positive and Negative Syndrome Scale (PANSS) total score, Young Mania Rating Scale (YMRS) score, the
percentage of patients on psychotropic medications as well as the chlorpromazine equivalent doses (CPZ) among patients on antipsychotics are presented. For adolescent patients, we also
show lifetime CPZ (CPZ years). Two and one adolescent patients were on antidepressants and antiepileptics, respectively. Correlations with logNSE [log10 neuron-specific enolase (NSE)] are
shown. p values <0.05 shown in bold.
aNumber of participants with data in each variable.
bChi-squared test or t test.
cPoint-biserial correlation for binary variables; Spearman’s correlation for continuous variables.
dFemales had lower logNSE concentrations than males.
eAmong adults but not adolescents, whilst controlling for age, sex and scanner, the case-control difference in TGMV was still significant ( p < 0.001, and 0.157, respectively).
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plasma levels in both unmedicated (n = 30, mean age 26 years)
and lithium-treated patients (n = 15, mean age 26 years) with
BD during a manic episode relative to HC (n = 30, age matched)
(Machado-Vieira et al., 2007). Akcan et al. reported that patients
with chronic (n = 22, mean age 29 years) BD had lower serum
NSE levels than first episode (n = 24, mean age 25 years) BD
and HC (n = 19, mean age 25 years) (Akcan et al., 2018). By con-
trast, Karabulut et al. reported higher plasma NSE in patients with
chronic BD (n = 77, mean age 38 years) compared to patients with
early stage BD (n = 30, mean age 25 years) and HC (n = 30, mean
age 32 years) (Karabulut et al., 2019). Finally, Tsai et al. reported
no serum NSE level difference between patients with BD in a
manic state (n = 17, mean age 37 years) and HC (n = 30, mean
age 34 years), and among patients no changes in NSE levels
after treatment (Tsai & Huang, 2017).
The discrepancy between our results and some of the previous
studies on circulating NSE might be due to the large differences in
sample sizes. None of the previous original studies included more
than 150 participants whereas we investigated 1132 adult patients
with SMI and 903 adult HC as well as 32 adolescent patients with
SMI and 67 adolescent HC yielding a substantial increase in
power and the advantage of using two independent samples
representing different ages. Interestingly, the meta-analysis in
BD included 251 patients and 145 HC, and showed non-
significantly lower circulating NSE levels in patients with high
heterogeneity across studies (Bartoli et al., 2020). Further, NSE
is present in platelets in much lower but not negligible levels com-
pared to the cortical brain tissue (Marangos, Campbell,
Schmechel, Murphy, & Goodwin, 1980a), and we cannot exclude
that the use of serum v. plasma as in the present study could have
contributed to the discrepancy due to the release of platelet com-
ponents such as NSE during coagulation of serum in vitro (Yu
et al., 2011).
We found significantly lower NSE levels not only in adult but
also in adolescent patients with SMI. Up to 18% of patients with
psychosis develop their first episode before reaching adulthood,
and they may be at higher risk of poor outcome relative to the
patient group with the adult-onset type of the disorder
(Diaz-Caneja et al., 2015). In addition to replicating the result
from the much larger adult sample, we can show that the lower
plasma NSE concentrations in patients with SMI are present
already in adolescence close to the disease onset (median DOI
1 year). This might support the notion that the lower NSE levels
are related to an underlying disease mechanism rather than being
an epiphenomenon of longstanding disease. Furthermore, the
patient/control status–NSE association was stronger in adoles-
cents with 7.4% of the variance in logNSE explained by the
patient-control status v. 1.3% in adults, which may further sup-
port the notion of NSE involvement in neurodevelopment.
Adolescence represents the second period of major neurodevelop-
ment with abundant ongoing maturation processes (Arain et al.,
2013) and may be a window of increased susceptibility to neuro-
developmental disturbances (Brent et al., 2013). Among adoles-
cent patients, the DOI was inversely correlated with NSE which
may reflect this late neurodevelopmental disturbance with
decreasing NSE levels as the disorder progresses. Among adult
Fig. 1. Back-transformed plasma NSE means in (a) adult patients with SMI and HC and (b) adult patients with SZ and BD and HC. **p = 0.005, ***p < 0.001.
Fig. 2. Back-transformed plasma NSE means in adolescent patients
with SMI and adolescent HC. *p < 0.05.
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patients with SZ spectrum disorders, NSE levels were inversely
associated with PANSS total, positive and general score, while
among adult patients with BD spectrum disorders with PANSS
positive score. These observations raise the possibility that lower
NSE might be related to a more severe form of SMI.
Among adults and adolescents, females (patients and HC
combined) had significantly lower circulating NSE than males.
In adults, this difference was present in both HC and patients.
A recent study investigating serum NSE in over 10 000 healthy
adults (20–79 years) reported no significant difference between
men and women (Liu et al., 2019). Another study investigating
901 healthy individuals reported a sex-by-age interaction. In par-
ticular, women had lower serum NSE levels compared to men in
younger ages (<60 years) and higher in older ages (Hoffmann
et al., 2017). This is partially in line with our result showing
lower NSE levels in healthy adult women than in healthy men
(age range 18–65 years). We did not find sex-by-age interactions
on logNSE in patients and HC combined, patients or HC (online
Supplementary Material). In line with our finding, the female
brain has been shown to have lower metabolic age indicating pres-
ervation of developmental attributes (Goyal et al., 2019).
We found that the subgroup of adult patients who currently
did not use psychotropic medication still had significantly lower
NSE levels than HC indicating that the NSE level differences
found in our main analyses were not confounded by psychotropic
medication use in patients. Further, among adult patients the
antipsychotic dosage as well as the use of lithium were both posi-
tively correlated with NSE levels. We are thereby tempted to
speculate that antipsychotics and lithium ameliorate the
SMI-related maturation disturbance. This notion is supported
by animal studies showing that antipsychotics enhance differenti-
ation and maturation in dentate gyrus (Chen et al., 2013) and
oligodendrocyte precursor cells (Xu, Yang, & Li, 2014) while lith-
ium has been shown to enhance the differentiation of neural pro-
genitor cells (Su, Chu, & Wu, 2007; Su et al., 2009).
Our results, indicating a lack of progressive neuronal damage,
are in line with other reports indicating an absence of neurode-
generation in SMI (Barth et al., 2020; Haukvik et al., 2016;
Zipursky, Reilly, & Murray, 2013). The neurodevelopmental
model has mainly been discussed for SZ (Kahn et al., 2015;
Zipursky et al., 2013), whereas in BD a neurodevelopmental
pathogenesis is more controversial (Kloiber et al., 2020). Our
results can be interpreted as an additional indication of neurode-
velopmental origin and lack of substantial neurodegeneration in
both disorders. Although there may be different underlying
mechanisms across and within diagnostic categories, the findings
are in line with the clinical observation that patients with SMI
may achieve long-term stability and to some extent even recovery.
Of note, whereas the lack of knowledge as well as attribution to
genetics may increase stigmatising attitudes towards patients
(Hawke et al., 2013; Serafini et al., 2011; Valery & Prouteau,
2020), recovery-oriented strategies can facilitate destigmatisation
(Valery & Prouteau, 2020).
The present study has certain limitations. Due to the multiple
and partially unknown role of NSE (Haque et al., 2018; Isgro
et al., 2015), we cannot rule out alternative interpretations of
the reduced NSE levels in SMI. NSE is a glycolytic enzyme
(Isgro et al., 2015) and its reduced circulating levels may reflect
impaired neuronal glycolytic capacity in SMI. NSE is also present
in the cytoplasm of central and peripheral neuroendocrine cells
(Marangos & Schmechel, 1987) and is elevated in patients with
neuroendocrine tumours (Isgro et al., 2015). Thus, we cannot
rule out that the observed lower NSE levels in SMI reflect dysfunc-
tion within neuronal glycolysis or the neuroendocrine system.
Another limitation of the study is the inclusion of both inpatients
and outpatients diagnosed with SZ or BD spectrum disorders. We
note, however, that when the two diagnostic categories were ana-
lysed separately, both showed significantly lower NSE levels than
HC. Moreover, although the overall number of participants was
high, the number of adolescent patients was rather low. Further,
as the distribution of the NSE concentrations in both adolescents
and adults was highly positively skewed, we used the log10-
-transformed NSE variable, which may have implications for
the interpretation of the results (Feng et al., 2014). To deal with
this limitation, we ran sensitivity analyses with nonparametric sta-
tistics, where we used the original NSE variable, and confirmed
the main results showing significantly lower NSE concentrations
in adults (both for SZ and BD spectrum) and adolescents with
SMI compared with HC (online Supplementary Material).
Finally, we cannot exclude that a portion of the measured NSE
originates from platelet-stored NSE (Marangos et al., 1980a)
release during freeze and thaw cycles. However, we believe it is
unlikely that there is a differential platelet-stored NSE release in
patients and HC that can generate the observed case-control
plasma NSE difference.
To conclude, we found significantly lower circulating NSE con-
centrations in both adult and adolescent patients with SMI com-
pared to HC. As an elevated NSE is considered to reflect
neuronal injury, whereas lower NSE may index neuronal matur-
ation disturbances, our results support the notion of abnormal neu-
rodevelopmental rather than neurodegenerative processes in SMI.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291721003056
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